Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

5-Hydroxytyptamine (Serotonin)

This presentation is about the neurotransmitter 5-HT (serotonin), we focused on its definition, biosynthesis, storage and destruction, with mentioning its both central and peripheral effects, and lastly the serotonin receptors in the human body, as well as their agonist and antagonists.

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all
  • Be the first to comment

5-Hydroxytyptamine (Serotonin)

  1. 1. 5-HYDROXYTRYPTAMINE Hawler Medical University College of Medicine Department of Pharmacology Prepared by: Zanyar Sabah Aram Majeed Ibrahim Hussein
  2. 2. Contents • Definition • Biosynthesis • Storage • Destruction • Central effects • Peripheral effects • 5-hydroxytryptamine receptors • 5-hydroxytryptamine receptor agonists • 5-hydroxytryptamine receptor antagonists
  3. 3. 5-HYDROXYTRYPTAMINE • Serotonin was the name given to the vasoconstrictor substance which appeared in the serum when blood clotted and Enteramine to the smooth muscle contracting substance present in enterochromaffin cells of gut mucosa.
  4. 4. • In early 1950s both were shown to be 5-Hydroxytryptamine ( 5-HT ) . About %90 of body’s content of 5-HT is localized in the intestines, most of the rest in the platelets and brain.
  5. 5. • It is also found in wasp and scorpion sting , and is widely distributed in invertebrates and plants (banana, pear, pineapple, tomato, stinging nettle, cowage).
  6. 6. Biosynthesis, Storage and Destruction 5-HT occurs in the highest concentrations in three situation in the body. • In the wall of intestine about %90 of the total amount in the body is present in enterochromaffin cells, which are cells derived from neural crest . • Similar to those of the adrenal medulla , that are interspersed with mucosal cells , mainly in the stomach and small intestine . Some of 5- HT also occurs in nerve cells of myenteric plexus , where it functions as an excitatory neurotransmitter
  7. 7. Biosynthesis, Storage and Destruction • In blood 5-HT is present in high concentration in platelets which accumulate it from the plasma by an active transport system and release it when they aggregate at sites of tissue damage. • In the CNS 5-HT is a transmitter in the CNS and is present in high concentrations in localised region of the midbrain . Though 5-HT is present in diet , most of this is metabolized before entering the blood stream.
  8. 8. Biosynthesis, Storage and Destruction • Endogenous 5-HT arises by biosynthesis , which follows a pathway similar to that of noradrenaline , except the precursor amino acid is tryptophan instead of tyrosine . • Tryptophan is converted to 5-Hydroxy tryptamine ( in chromaffin cells and neurons, but not in platelets ) by the action of tryptophan hydroxylase ( an enzyme confined to 5-HT producing cells ) .
  9. 9. Biosynthesis, Storage and Destruction • The 5-hydroxytreptophan is then decarboxylated to 5-HT , by a ubiquitous amino –acid decarboxylase that also participates in the synthesis of cathecholamines and histamine . • Platelets (and neurons) possess a high affinity 5-HT uptake mechanism , and platelets become loaded with 5-HT as they pass through the intestinal circulation , where the local concentration is relatively high .
  10. 10. Biosynthesis, Storage and Destruction • 5-HT is often stored in neurons and chromaffin cells as a co- transmitter together with various peptide hormones , such as somatostatin. • Substance P or vasoactive intestinal polypeptide (VIP). Degradation of 5-HT occurs mainly through oxidative deamination , catalysed by monoamine oxidase , followed by oxidation to 5-hydroxyindoleacetic acid ( 5-HIAA ) .
  11. 11. Biosynthesis, Storage and Destruction • The pathway being the same as that of noradrenaline catabolism . 5- HIAA is excreted in the urine and serves as an indicator of 5-HT production in the body , this is used for example , in the diagnosis of carcinoid syndrome .
  12. 12. Pharmacological effects 1- Central effects Hallucinatory effects Many hallucinogenic drugs (e.g. LSD) are agonists at 5-HT2A receptors and depress the firing of brain-stem 5-HT neurons, these neurons exert an inhibitory influence on cortical neurons
  13. 13. Sleep, wakefulness and mood There is evidence that 5-HT may be involved in the control of mood and the use of tryptophan to enhance 5-HT synthesis has been tried in depression, with equivocal results Feeding and appetite Antagonists acting on 5-HT2 receptors, including several antipsychotic drugs used clinically, also increase appetite and cause weight gain. On the other hand, antidepressant drugs that inhibit 5-HT uptake cause loss of appetite.
  14. 14. Sensory transmission After lesion of the raphe nuclei or administration of para- chlorophenylalanine animals show exaggerated responses to many forms of sensory stimulus. 5-HT also exerts an inhibitory effect on transmission in the pain pathway.
  15. 15. Other possible roles Other putative role of 5-HT include various autonomic and endocrine functions such as the regulation of body temperature, blood pressure, vomiting and sexual function.
  16. 16. Pharmacological effects 2- Peripheral effects Gastrointestinal Tract Stimulates motility Nausea and vomiting
  17. 17. Smooth muscle Contraction, to a minor extent in humans Blood vessels Size, species, prevailing sympathetic activity Arteries and veins constricted Arterioles dilate while venules constrict If 5-HT is injected IV, BP first then
  18. 18. Platelet Platelet aggregation via 5-HT2A receptors and they release more 5-HT. Nerve endings Stimulates nociceptive sensory nerve endings via 5-HT3 receptors. Glands Inhibits gastric secretions but increases mucus secretion.
  19. 19. 5-Hydroxytryptamine Receptors Seven families of 5-HT receptors (5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, 5-HT7 )
  20. 20. All 5-HT receptors are G protein coupled receptors, except 5-HT3 which is a Ligand gated ion channel, its activation elicits fast depolarization. Function through: 5-HT1 : decreasing cAMP production 5-HT2 : produce IP3/DAG 5-HT4,7 : increasing cAMP production
  21. 21. 5-HT1 receptors Occur mainly in the brain The 5-HT1A subtype is particularly important in the brain, in relation to mood and behaviour. The 5-HT1D subtype, which is expressed in cerebral blood vessels, is important in migraine and is the target for Sumatriptan.
  22. 22. 5-HT2 receptors Particularly important in the periphery Stimulate IP3 /DAG formation The 5-HT2A subtype is functionally the most important, mediates smooth muscle contraction and platelet aggregation.
  23. 23. 5-HT3 receptors Occur mainly in the PNS, particularly on nociceptive sensory neurons and autonomic and enteric neurons, 5-HT3 receptors also occur in the brain, particularly in the area postrema, a region of the medulla involved in the vomiting reflex.
  24. 24. 5-HT4 receptors Occur in the brain, as well as in peripheral organs such as the GIT, bladder and heart. Their main physiological role appears to be in the GIT where they produce neuronal excitation and mediate the effect of 5-HT in stimulating peristalsis.
  25. 25. 5-Hydroxytryptamine Receptor Agonists Selective 5-HT1A agonists : 8-hydroxy-2-(di-npropylamino) tetralin (8-OH DPAT) highly selective agonist but not used clinically Buspirone, Gepirone, Ipasapirone : potent 5-HT1A agonists used in treating anxiety. Given orally at a dosage of 15 mg/day the drug is rapidly absorbed half-life of about 2.5 hours The mean peak plasma concentration (Cmax) is approximately 2.5 μg/L, and the time to reach the peak is under 1 hour, however it takes days or weeks to produce its effect. The absolute bioavailability of buspirone is approximately 4%.
  26. 26. Side effects: Mainly nausea, dizziness, headache, restlessness but no sedation or loss of coordination.
  27. 27. 5-HT1D receptor agonists Sumatriptan, used for treating migraine Pharmacokinetics: Administered subcutaneously, orally, and intranasally. Orally, single dose of 25, 50, or 100 mg, if patient has a partial response to the initial dose, a single additional dose may be taken after 2 h up to a max of 200 mg/day Subcutaneous 6 mg initially. May repeat once after 1 h (max, 6 mg per single dose or 12 mg/day). Intranasal Administer a single dose of 5, 10, or 20 mg in one nostril. The dose may be repeated once after 2 h (max, 40 mg/day).
  28. 28. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. Bioavailability for subcutaneous, oral, and intranasal administration is 97%, 15%, and 15.8%, respectively. Metabolized by MAO-A Contraindicated in patients with severe hepatic impairment, patients with history or symptoms of ischemic heart disease, cerebrovascular syndromes (strokes) or peripheral vascular syndromes (ischemic bowel disease).
  29. 29. 5-HT4 receptor agonists Metoclopramide which stimulate coordinated peristaltic activity (prokinetic action), are used for treating gastrointestinal disorders, increase motility Pharmacokinetics: Given orally at a dose of 5-10 mg, is rapidly and well absorbed, bioavailability is 80% ± 15.5%, plasma half life or 4-5 h and peak plasma concentrations occur at about 1 to 2 h. 85% eliminated in the urine.
  30. 30. Side effects : Fatigue, motor restlessness, spasmodic torticollis, occulogyric crisis, also can cause galactorrhoea and disorders of menstruation. Contraindications : Metoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. patients with pheochromocytoma, should not be used in epileptics or patients receiving other drugs, which are likely to cause extrapyramidal reactions
  31. 31. • Tegaserod is more selective and is used to treat irritable bowel syndrome. Tegaserod at dosages of 1 to 12 mg/day exerts pharmacodynamic actions in the upper and the lower gastrointestinal tract, accelerating small bowel and colonic transit in patients with IBS. It is rapidly absorbed following oral administration, peak plasma concentrations are reached after approximately 1 hour. Absolute bioavailability is about 10% under fasted conditions, food reduces the bioavailability of tegaserod by 40 to 65%. Tegaserod is approximately 98% bound to plasma proteins, primarily to alpha(1)-acid glycoprotein
  32. 32. • Approximately two-thirds of the orally administered dose of tegaserod is excreted unchanged in faeces, with the remainder excreted in urine,
  33. 33. 5-Hydroxytryptamine Receptor Antagonists 5-HT2 receptor antagonists : Cyproheptadine: primarily blocks 5-HT2A receptor, used in controlling the symptoms of carcinoid tumors. Methysergide & Dihydroergotamine: used mainly for migraine prophylaxis. Ketanserin: 5HT2 (blockade of 5HT2A is stronger than of 5HT2C) and α1 antagonist, used as antihypertensive. Clozapine: partial antagonist at 5-HT2A/2C receptor, Risperidone: is a combined 5-HT2A + dopamine D2 antagonist,
  34. 34. Clozapine and Risperidone are both used in treatment of schizophrenia. Are recent (atypical) antipsychotics They can be given orally or IM injection, They take days or weeks to show their effects The absorption of clozapine is almost complete, but the oral bioavailability is only 60 to 70%.The time to peak concentration after oral dosing is about 2.5 hours, and food does not appear to affect the bioavailability of clozapine. The elimination half-life of clozapine is about 14 hours at steady state conditions (varying with daily dose). Clozapine is extensively metabolized in the liver, via the cytochrome P450 system, to polar metabolites suitable for elimination in the urine and feces.
  35. 35. Side effects : Clozapine is usually used only in patients that have not responded to other anti-psychotic treatments due to its danger of causing agranulocytosis. Common side effects include extreme constipation, night- time drooling, muscle stiffness, sedation, tremors, hyperglycemia, and weight gain. The risk of developing extrapyramidal symptoms such as tardive dyskinesia is below that of typical antipsychotics.
  36. 36. 5-HT3 receptor antagonists : Ondansetron, Granisetron, Tropisetron: These agents have an important place in treating emesis linked with chemotherapy. Long duration of action. Can be administered as a single dose prior to chemotherapy. Are extensively metabolized in the liver. Elimination is through the urine. Common side effect is headache.
  37. 37. 5-HT mixed agonist and antagonist : Lysergic acid diethylamide (LSD) Is a potent hallucinogen, activates 5-HT1A, 5-HT2A/2C, 5-HT5-7, also antagonizes 5-HT2A receptors in the ileum.
  38. 38. • Other related drugs : SSRI : specifically inhibit serotonin reuptake, have 300-3000 fold selectivity, drug of choice in treating depression. Example : Fluoxetine, citalopram, fluvoxamine, paroxetine, sertraline, Indication : Depression, obsessive compulsive disorder, panic disorder, generalized anxiety and bulimia nervosa.
  39. 39. Mechanism of action of SSRIs
  40. 40. • Pharmacokinetics : All the SSRIs are well absorbed after oral administration. All have large volume of distribution. Plasma half lives range between 16-36 h but Fluoxetine have a half life of 50 h. Fluoxetine and paroxetine are inhibitors of enzyme CYP2D6. Excretion is primarily through the kidneys, except Paroxetine and Sertraline undergo 35% fecal excretion, 50% renal excretion. Dosage should be adjusted downward in hepatic impairment.
  41. 41. Adverse effects : Nausea, vomiting, diarrhea, Headache, restlessness, fatigue, sleep disturbances. Should be used cautiously in children and teenagers, 1 out of 50 children become suicidal as a result of SSRI treatment,
  42. 42. Summary Receptor Location Effect 1A CNS Neuronal inhibition, behavioural effects: sleep, feeding, thermoregulation, anxiety. 1B CNS, Presynaptic inhibition, Vascular smooth muscle Pulmonary vasoconstriction 1D CNS, Cerebral vasoconstriction Blood vessels Behavioural effects: locomotion 2A CNS, PNS, Neuronal excitation Smooth muscle Smooth muscle contraction platelets Platelet aggregation 2B Gastric fundus Contraction
  43. 43. Summary Receptor Location Effect 2C CNS, Cerebrospinal fluid secretion Choroid plexus 3 PNS Neuronal excitation (autonomic, nociceptive n) CNS, Emesis, anxiety 4 CNS, PNS (GIT) Neuronal excitation, Gl motility 5 CNS Not known 6 CNS Not known 7 CNS, GIT Not known Blood vessels
  44. 44. References 1- Rang H P, Dale M M, Ritter J M, Moore P K, Pharmacology. 5th Ed.Churchill Livingstone:London;2003 2- Richard D.howland & Mary J.mycek. Lippincott's Illustrated Reviews: Pharmacology, 3rd Ed.USA:Lippincott Williams & wilkins; 2006 3- Tripathi K D, Eseentials of medical pharmacology. 6th Ed. Jaypee:New Delhi; 2007

    Be the first to comment

    Login to see the comments

  • RonyJames6

    Apr. 12, 2020
  • VijayJaiswal56

    Apr. 24, 2020
  • VasanthKulo

    Apr. 30, 2020
  • PoojaMehta111

    May. 2, 2020
  • BhumikaNagaraj

    May. 9, 2020
  • Nkienstayelle

    Jun. 26, 2020
  • EleanorFonji

    Jul. 7, 2020
  • KingKeddy

    Jul. 10, 2020
  • Selimrezasetu

    Jul. 27, 2020
  • PraveenUpadhyay30

    Sep. 9, 2020
  • anilanand184

    Sep. 30, 2020
  • vishnuprasad344

    Oct. 23, 2020
  • ManasaPriya9

    Oct. 27, 2020
  • KrishnaKumar2100

    Dec. 3, 2020
  • SasithaSrisunitha

    Jan. 7, 2021
  • SarahGadavala

    Jan. 8, 2021
  • TabassumBanna

    Feb. 7, 2021
  • ManuSingh163

    Feb. 20, 2021
  • ArpanBanerjee41

    May. 19, 2021
  • MonikaChauhan84

    Jun. 5, 2021

This presentation is about the neurotransmitter 5-HT (serotonin), we focused on its definition, biosynthesis, storage and destruction, with mentioning its both central and peripheral effects, and lastly the serotonin receptors in the human body, as well as their agonist and antagonists.


Total views


On Slideshare


From embeds


Number of embeds